Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) Shares Outstanding (Weighted Average): 2020-2024

Historic Shares Outstanding (Weighted Average) for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Dec 2024 value amounting to $46.2 million.

  • 4D Molecular Therapeutics' Shares Outstanding (Weighted Average) fell 10.14% to $46.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.7 million, marking a year-over-year decrease of 10.14%. This contributed to the annual value of $46.2 million for FY2024, which is 8.13% up from last year.
  • Per 4D Molecular Therapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $46.2 million for FY2024, which was up 8.13% from $42.8 million recorded in FY2023.
  • Over the past 5 years, 4D Molecular Therapeutics' Shares Outstanding (Weighted Average) peaked at $46.2 million during FY2024, and registered a low of $23.8 million during FY2020.
  • Over the past 3 years, 4D Molecular Therapeutics' median Shares Outstanding (Weighted Average) value was $42.8 million (recorded in 2023), while the average stood at $40.5 million.
  • Data for 4D Molecular Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY soared of 34.85% (in 2021) over the last 5 years.
  • 4D Molecular Therapeutics' Shares Outstanding (Weighted Average) (Yearly) stood at $23.8 million in 2020, then skyrocketed by 34.85% to $32.1 million in 2021, then grew by 0.79% to $32.4 million in 2022, then surged by 31.99% to $42.8 million in 2023, then increased by 8.13% to $46.2 million in 2024.